Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Christine Poon Sells 7,830 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Christine Poon sold 7,830 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the transaction, the director owned 5,219 shares of the company’s stock, valued at $5,057,680.71. This represents a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $42.69 on Wednesday, hitting $930.67. The stock had a trading volume of 1,383,115 shares, compared to its average volume of 830,923. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. The firm’s 50 day moving average price is $798.74 and its 200-day moving average price is $740.16. The company has a market capitalization of $95.82 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.83 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 8.30%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an “equal weight” rating in a research report on Monday. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target for the company in a report on Thursday, October 1st. HSBC lifted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Sanford C. Bernstein boosted their price objective on Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the stock a “market perform” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $898.97.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Kestra Investment Management LLC raised its position in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 16 shares during the last quarter. AlphaCore Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 133.5% during the 3rd quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock worth $1,215,000 after buying an additional 916 shares in the last quarter. Leuthold Group LLC boosted its position in Regeneron Pharmaceuticals by 11.2% in the 3rd quarter. Leuthold Group LLC now owns 10,303 shares of the biopharmaceutical company’s stock valued at $7,812,000 after buying an additional 1,038 shares during the last quarter. Fulcrum Asset Management LLP bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $519,000. Finally, StoneRidge PMG Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $610,000. 83.31% of the stock is owned by institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks says improving earnings estimates could help support further near-term gains in REGN shares, following the stock’s recent advance. Why Regeneron Might Be Well Poised for a Surge
• Positive Sentiment: Analysts have raised price targets and several firms have expressed confidence in further appreciation. This follows Regeneron’s strong third-quarter results: revenue rose 36.3% year over year to $5.12 billion and EPS of $20.07 beat consensus of $16.51. Coverage also cited commercial performance and pipeline progress. RBC raises its price target Cantor Fitzgerald outlook Q3 results and pipeline coverage
• Neutral Sentiment: Director Kathryn Guarini sold 400 shares for $360,000 under a pre-arranged Rule 10b5-1 plan. The planned sale is less informative as a signal about the company’s outlook. Director share sale
• Negative Sentiment: The recent rally may leave room for valuation-related caution: some analyst targets remain below the share price, even as other firms have lifted their forecasts. The articles do not identify a fresh company-specific setback behind Wednesday’s weakness.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.